Mis-selling

The most common form of financial harm in India, and the one least likely to involve anybody lying.

The definition

Mis-selling is a deemed unfair trade practice under regulation 4(2)(s), and the Explanation defines it as the sale of securities or services relating to the securities market, by any person, directly or indirectly, by:

1. "knowingly making a false or misleading statement", or
2. "knowingly concealing or omitting material facts", or
3. "knowingly concealing the associated risk", or
4. "not taking reasonable care to ensure suitability of the securities or service to the buyer"

Notice the asymmetry. The first three require knowingly. The fourth does not. It requires only a failure to take reasonable care — and the limbs are disjunctive, joined by "or", so the fourth stands alone.

That is the whole chapter in one observation. You can commit mis-selling in India without making any false statement, without concealing anything, and without knowing you have done it. Selling something that does not suit the buyer, without having taken reasonable care to find out, is sufficient.

Why the fourth limb is the one that matters

The first three describe conduct most people would recognise as wrong, and they are relatively rare, because they require a state of mind that is hard to maintain and embarrassing to admit.

The fourth describes an omission, which requires nothing except an incentive and no process. It is therefore the normal case.

And it has a defined content. "Reasonable care to ensure suitability" is not left to intuition — chapter 5's regulations 16 and 17 spell out what the care consists of: age, objectives and horizon, income, existing assets, risk tolerance, liabilities; assessing what the buyer is both willing and able to bear; a documented selection process; and a reasonable basis for believing the product meets their objectives and that they can bear its risks. A seller who did none of that has a hard time arguing the care was taken.

How unsuitable products reach people

Chapter 3's argument, now concrete. No step requires bad faith.

Commission differentials set what gets offered. The seller's menu is not the market; it is the subset that pays them. A product paying nothing is not withheld deliberately — it is simply never learned, never trained on, never top of mind.

Complexity defeats comparison. Where a product cannot be compared to an alternative, the buyer cannot discover it is expensive. Bundles — investment plus insurance — are the clearest case, because no unbundled benchmark is visible.

The sale is framed on the outcome, not the cost. A projected maturity value is a large, attractive number. The charges that produce the gap between contributions and that value are distributed across several deductions, and chapter 6 of the Behavioural finance subject explains why the framing works.

Documentation substitutes for assessment. Signatures accumulate. Every signature makes the file look better and none of them establishes that anybody considered whether the thing suited the buyer. A complete file is evidence of compliance activity, not of suitability.

Exit penalties arrive later. Early-year charges and surrender terms mean the buyer who discovers the mistake in year two cannot leave without crystallising it, which is also why mis-selling tends to be discovered long after the trail commission has been paid.

Working the problem

A 61-year-old with no dependants, living on her savings income, sold a long-dated unit-linked policy with heavy early-year charges. Everything signed.

The case that this is mis-selling, under limb four:

She has no insurance need. No dependants means no one suffers financial loss on her death, and the life-cover component of the product is the part she is paying for and cannot use. Selling insurance to someone with nobody to insure against their death is the clearest possible suitability failure.

The term does not fit her horizon. Regulation 16 requires the time for which the buyer wishes to stay invested and the purposes of the investment. At 61 and living on her savings income, a long-dated contract with punitive early exit is close to the opposite of what her stated purpose requires.

Her income need was not served. She lives on the income from her savings. The product converts an income-producing pool into a long-term contract that produces none until maturity, which attacks her actual cash flow.

Capacity to bear loss was not assessed. Regulation 16 requires assessing capacity for absorbing loss and whether the buyer is unable to accept loss of capital. Someone dependent on their capital for living expenses has very low capacity, which is a fact about her, not a preference.

The signatures do not answer it. Limb four is not about disclosure or consent — it asks whether reasonable care was taken to ensure suitability. Disclosure is a different obligation, discharged by a different act, and chapter 3 explained why consent to a conflicted recommendation is a weak protection. Signing a document that says you understand the risk is not the same as the risk being appropriate for you.

The strongest defence:

She asked for it. If she sought out this product, perhaps on a relative's recommendation, and declined alternatives after they were explained, the seller is closer to an execution role than an advisory one. A documented, informed, unsolicited instruction is a genuine answer, because reasonable care is owed in a sale, not in the face of a customer's own insistence — and the defence is only as good as its documentation.

It may not be a securities-market product. Regulation 4(2)(s) reaches "securities or services relating to securities market". A unit-linked insurance policy is an insurance contract regulated by IRDAI, so the applicable regime may be the insurance one rather than this SEBI provision. This is chapter 2's seam, arriving exactly where predicted — the bundle sits between two regulators, and which door her complaint goes through is itself contestable. The suitability concept exists in both regimes, so the substance of her complaint survives; the forum is the uncertainty.

No advisory relationship was held out. If the seller was a distributor rather than an investment adviser, chapter 5's fiduciary duty and regulation 15(2) do not apply to them. Limb four still does, since it binds "any person", but the standard of care expected of a distributor is lower than that expected of an adviser.

Which prevails. On the merits the suitability case is very strong, because the insurance component is unusable by her and her living expenses depend on the capital. The real contest is procedural — which regulator, which standard of care, and what the file shows about who proposed the product. That is a fair description of most real mis-selling disputes: the substance is clear and the forum is the fight.

What this implies for you

Ask what the alternative was and why it lost. A seller who cannot name the cheaper option they rejected has not run a selection process.

Ask about your liabilities and notice if they do not. Regulation 16 requires it, and its absence is diagnostic.

Ask what happens if you exit in year three. Early-exit terms reveal the charge structure better than any disclosure document.

Separate protection from investment. Price the term cover alone. The bundle's cost is only visible against the unbundled alternative.

Treat your own signature as worth nothing to you. It protects the seller. Only the suitability question protects you.

The point

Indian law defines mis-selling in four limbs, three requiring knowledge and the fourth requiring only a failure to take reasonable care to ensure the product suits the buyer — and because the limbs are alternatives, mis-selling can be committed with no false statement and no awareness of wrongdoing. The content of "reasonable care" is supplied by the profiling and suitability rules: age, horizon, income, assets, risk tolerance, liabilities, capacity to bear loss, a documented process and a reasoned basis. A complete signed file evidences compliance activity rather than suitability, and in bundled investment-insurance products the hardest question is usually which regulator's door the complaint goes through rather than whether the sale was unsuitable.